Clarivate Plc (NYSE:CLVT) shares traded 3.79% higher at $8.76 on Wall Street last session.
CLVT stock price is now 24.00% away from the 50-day moving average and 7.80% away from the 200-day moving average. The market capitalization of the company currently stands at $5.82B.
With the price target reduced from $10 to $8.50, Jefferies Upgraded its rating from Hold to Buy for Clarivate Plc (NYSE: CLVT).
Insiders disposed of 234,869 shares of company stock worth roughly $2.06 million over the past 1 year. A total of 42.16% of the company’s stock is owned by insiders.
During the past 12 months, Clarivate Plc has had a low of $6.07 and a high of $11.99. As of last week, the company has a debt-to-equity ratio of 0.74, a current ratio of 0.94, and a quick ratio of 0.94. According to the stock market information, the enterprise value for the company is $11.77B, which is based on a 39.16 price-to-earnings ratio, a 6.87 price-to-earnings-growth ratio, and a beta of 1.30. The fifty day moving average price for CLVT is $7.06 and a two-hundred day moving average price translates $8.13 for the stock.
The latest earnings results from Clarivate Plc (NYSE: CLVT) was released for Sep, 2023. According to the Information Technology Services Company, earnings per share came in at $0.21, beating analysts’ expectations of $0.18 by 0.03. This compares to -$6.54 EPS in the same period last year. The net profit margin was 6.90% and return on equity was 4.02% for CLVT. The company reported revenue of $647.2 million for the quarter, compared to $635.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.81 percent. For the current quarter, analysts expect CLVT to generate $678.42M in revenue.
Clarivate Plc(CLVT) Company Profile
Clarivate Plc, an information, analytics, and workflow company, provides structured information and analytics for discovery, development, protection, commercialization, and measurement of scientific research, innovations, and brands. The company operates through three segments: Academia and Government, Life Sciences and Healthcare, and Intellectual Property. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ProQuest One, Pivot, Polaris, eBook Central, Vegs, Alma, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis products for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs; and Real World Data, Dialog, Drug Safety Triager, and healthcare and data solutions. The company also provides Derwent products, which include Derwent Innovation, Innography, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; and CompuMark products, such as trademark screening, searching, and watching products and services. It serves government and academic institutions, and life science and healthcare companies in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc was founded in 1864 and is headquartered in London, the United Kingdom.
